Rimonabant: From RIO to Ban
Endocannabinoid antagonism as a treatment for obesity and the metabolic syndrome became a hugely anticipated area of pharmacology at the start of the century. The CB1 receptor antagonist Rimonabant entered the European mass market on the back of several trials showing weight loss benefits alongside...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Journal of Obesity |
| Online Access: | http://dx.doi.org/10.1155/2011/432607 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553721376014336 |
|---|---|
| author | Amir H. Sam Victoria Salem Mohammad A. Ghatei |
| author_facet | Amir H. Sam Victoria Salem Mohammad A. Ghatei |
| author_sort | Amir H. Sam |
| collection | DOAJ |
| description | Endocannabinoid antagonism as a treatment for obesity and the metabolic syndrome became a hugely anticipated area of pharmacology at the start of the century. The CB1 receptor antagonist Rimonabant entered the European mass market on the back of several trials showing weight loss benefits alongside improvements in numerous other elements of the metabolic syndrome. However, the drug was quickly withdrawn due to the emergence of significant side effects—notably severe mood disorders. This paper provides a brief overview of the Rimonabant story and places the recent spate of FDA rejections of other centrally acting weight loss drugs entering Phase 3 trials in this context. |
| format | Article |
| id | doaj-art-fd1c393f894b4564b5eb27ae2753773a |
| institution | Kabale University |
| issn | 2090-0708 2090-0716 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Obesity |
| spelling | doaj-art-fd1c393f894b4564b5eb27ae2753773a2025-02-03T05:53:30ZengWileyJournal of Obesity2090-07082090-07162011-01-01201110.1155/2011/432607432607Rimonabant: From RIO to BanAmir H. Sam0Victoria Salem1Mohammad A. Ghatei2Section of Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Hammersmith Hospital, Imperial College London, Du Cane Road, London W12 0NN, UKSection of Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Hammersmith Hospital, Imperial College London, Du Cane Road, London W12 0NN, UKSection of Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Hammersmith Hospital, Imperial College London, Du Cane Road, London W12 0NN, UKEndocannabinoid antagonism as a treatment for obesity and the metabolic syndrome became a hugely anticipated area of pharmacology at the start of the century. The CB1 receptor antagonist Rimonabant entered the European mass market on the back of several trials showing weight loss benefits alongside improvements in numerous other elements of the metabolic syndrome. However, the drug was quickly withdrawn due to the emergence of significant side effects—notably severe mood disorders. This paper provides a brief overview of the Rimonabant story and places the recent spate of FDA rejections of other centrally acting weight loss drugs entering Phase 3 trials in this context.http://dx.doi.org/10.1155/2011/432607 |
| spellingShingle | Amir H. Sam Victoria Salem Mohammad A. Ghatei Rimonabant: From RIO to Ban Journal of Obesity |
| title | Rimonabant: From RIO to Ban |
| title_full | Rimonabant: From RIO to Ban |
| title_fullStr | Rimonabant: From RIO to Ban |
| title_full_unstemmed | Rimonabant: From RIO to Ban |
| title_short | Rimonabant: From RIO to Ban |
| title_sort | rimonabant from rio to ban |
| url | http://dx.doi.org/10.1155/2011/432607 |
| work_keys_str_mv | AT amirhsam rimonabantfromriotoban AT victoriasalem rimonabantfromriotoban AT mohammadaghatei rimonabantfromriotoban |